Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells
Authors:
- 27 May 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 8 (24) , 15000-15012
Abstract
Functionalization can promote the uptake of nanoparticles into cancer cells via receptor-mediated endocytosis, enabling them to exert their therapeutic effects. In this paper, epigallocatechin gallate (EGCG), which has a high binding affinity to 67 kDa laminin receptor (67LR) overexpressed in HCC cells, was employed in the present study to functionalized ruthenium nanoparticles (RuNPs) loaded with luminescent ruthenium complexes to achieve antiliver cancer efficacy. [Ru(bpy)2(4-B)] (ClO4)2·2H2O (RuBB)-loaded EGCG-RuNPs (bpy = 2,2'-bipyridine) showed small particle size with narrow distribution, better stability, and high selectivity between liver cancer and normal cells. The internalization of RuBB-loaded EGCG-RuNPs was inhibited by 67LR-blocking antibody or laminin, suggesting that 67LR-mediated endocytosis played an important role in the uptake into HCC cells. Moreover, transmission electron microscopy and confocal microscopic images showed that RuBB-loaded EGCG-RuNPs accumulated in the cytoplasm of SMMC-7721 cells. Furthermore, our results indicated that the EGCG-functionalized nanoparticles displayed enhanced anticancer effects in a target-specific manner. Concentrations of RuBB-loaded EGCG-RuNPs, nontoxic in normal L-02 cells, showed direct reactive oxygen species-dependent cytotoxic, pro-apoptotic, and anti-invasive effects in SMMC-7721 cells. Furthermore, in vivo animal study demonstrated that RuBB-loaded EGCG-RuNPs possessed high antitumor efficacy on tumor-bearing nude mice. It is encouraging to conclude that the multifunctional RuNPs may form the basis of new strategies on the treatment of liver cancer and other malignancies.Keywords
Funding Information
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China (21171070, 21371075)
- Natural Science Foundation of Guangdong Province (2014A030311025, S2013010011660)
This publication has 53 references indexed in Scilit:
- Hepatic Resection Associated With Good Survival for Selected Patients With Intermediate and Advanced-Stage Hepatocellular CarcinomaAnnals of Surgery, 2014
- Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trialsInternational Journal of Cancer, 2013
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2011
- Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of DiseaseToxicological Sciences, 2011
- Hepatocellular carcinoma: a global viewNature Reviews Gastroenterology & Hepatology, 2010
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Randomized, Multicenter, Phase II Trial of Two Multicomponent Regimens in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 2003
- Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate CancerJournal of Urology, 2002
- Hepatocellular carcinoma: Diagnosis and treatmentGastroenterology, 2002